What is LOPJLB’s current signal on CYCC?

LOPJLB’s latest quantitative signal on Cyclacel Pharmaceuticals, Inc. (CYCC) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is CYCC in?

Cyclacel Pharmaceuticals, Inc. (CYCC) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Cyclacel Pharmaceuticals, Inc. (CYCC) do?

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical s…

Cyclacel Pharmaceuticals, Inc. (CYCC)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$97.68+1.75%Close

SELLCRISIS · day 30

RANGE

DATA 2024-12-05

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $163M
Beta: 0.16

P/E (TTM): -3.08

1W: +17.97%
1M: -7.94%

vs SPY 1W: +17.55%
vs SPY 1M: -10.00%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

FAQ

What is LOPJLB’s current signal on CYCC?: LOPJLB’s latest quantitative signal on Cyclacel Pharmaceuticals, Inc. (CYCC) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is CYCC in?: Cyclacel Pharmaceuticals, Inc. (CYCC) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Cyclacel Pharmaceuticals, Inc. (CYCC) do?: Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical s…

Key stats

Prediction markets

Company news

FAQ